ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.850
-0.440 (-13.37%)
At close: Mar 3, 2025, 4:00 PM
2.890
+0.040 (1.40%)
After-hours: Mar 3, 2025, 6:57 PM EST
ImmunityBio Employees
ImmunityBio had 628 employees as of December 31, 2023. The number of employees decreased by 97 or -13.38% compared to the previous year.
Employees
628
Change (1Y)
-97
Growth (1Y)
-13.38%
Revenue / Employee
$23,479
Profits / Employee
-$658,541
Market Cap
2.08B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 628 | -97 | -13.38% |
| Dec 31, 2022 | 725 | 138 | 23.51% |
| Dec 31, 2021 | 587 | 322 | 121.51% |
| Dec 31, 2019 | 265 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
IBRX News
- 4 days ago - ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer - Business Wire
- 12 days ago - FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage - Business Wire
- 18 days ago - ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
- 4 weeks ago - ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer - Business Wire
- 5 weeks ago - ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
- 6 weeks ago - ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval - Seeking Alpha
- 6 weeks ago - ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - Benzinga
- 6 weeks ago - ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency - Business Wire